EUVIMEDEUVIMED entdecken
Crossref

Ivermectin dosing for children under 2 years

Wenyu Yang, Andrew Steer, Ben Coghlan, Khampheng Phongluxa, Xiao Zhu iD, Amanda Gwee

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Wenyu Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fudan University, No. 826, Zhangheng Road, Pudong New Area, Shanghai, China. Hauptthemen laut MEDLINE: Ivermectin, Antiparasitic Agents, Scabies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Ivermectin is effective against scabies but not licensed for children weighing <15 kg. We aimed to identify an ivermectin dosing strategy for children aged <2 years.

Methods

Doses for three age subgroups under 2 years were simulated by incorporating a maturation function for metabolizing enzymes into a population pharmacokinetic (PopPK) model to achieve median plasma AUC0–∞ between 80% and 125% of that observed in children aged 5–15 years receiving the standard 200 μg/kg dose (AUC0–∞ 976 μg/L h). Patient covariates were sampled from the National Health and Nutrition Examination Survey dataset. Final doses were rounded to feasible fractions of a 3 mg tablet.

Results

For infants aged 3–7 months, a 0.75 mg dose (one-fourth tablet) resulted in a median AUC0–∞ of 835 μg/L h [IQR: 632–1017]; for 8–12 months, a 1.5 mg dose (one-half tablet) yielded 848 μg/L h [IQR: 774–934]; and for 13–24 months, a 3 mg dose (one tablet) resulted in 1033 μg/L h [IQR: 943–1173]. All doses achieved median exposures within 80%–125% of the reference AUC in older children.

Conclusions

A dosing strategy for ivermectin in children aged 3 months–2 years was developed using a CYP3A4 maturation-based PopPK model. This regimen will be evaluated in an upcoming clinical trial to inform safe and effective scabies treatment in young children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvermectinAntiparasitic AgentsScabiesHumansInfantMaleFemaleChild, PreschoolAdolescentChildArea Under Curve

Substanzen

IvermectinAntiparasitic Agents

Autor:innen und Institutionen

  • School of Pharmacy, Fudan University, No. 826, Zhangheng Road, Pudong New Area, Shanghai, China.
  • The Royal Children's Hospital Melbourne, 50 Flemington Rd, Parkville, Victoria, Australia.
  • Murdoch Children's Research Institute, 50 Flemington Rd, Parkville, Victoria, Australia.
  • Burnet Institute, Melbourne, Victoria, Australia.
  • Lao Tropical and Public Health Institute, Ministry of Health, Samsenthai Road, Ban Koagnot, Sisattanack District, Vientiane Capital, Lao PDR.
  • Department of Paediatrics, The University of Melbourne, 50 Flemington Rd, Parkville, Victoria, Australia.

ORCID-Profile: Xiao Zhu

Zitieren

APA

Yang, W., Steer, A., Coghlan, B., Phongluxa, K., Zhu, X., & Gwee, A. (2025). Ivermectin dosing for children under 2 years. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf344

Vancouver

Yang W, Steer A, Coghlan B, Phongluxa K, Zhu X, Gwee A. Ivermectin dosing for children under 2 years. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf344

BibTeX
@article{Yang2025,
  author = {Yang, Wenyu and Steer, Andrew and Coghlan, Ben and Phongluxa, Khampheng and Zhu, Xiao and Gwee, Amanda},
  title = {Ivermectin dosing for children under 2 years},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf344}
}
Kostenlos starten →